Designing an Implementation Strategy for Lung Screening and Smoking Cessation Treatment in Community Health Centers

NCT ID: NCT05447897

Last Updated: 2024-04-16

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 9 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2022-12-01
• Study Completion Date: 2023-05-31

Brief Summary

Tobacco use is the leading preventable cause of death in the US and a major driver of health disparities. Among our tools for reducing the harms of tobacco is lung cancer screening (LCS). This study will combine a review of existing qualitative and quantitative data on barriers to lung cancer screening and smoking cessation in underserved populations, a quantitative analysis of predictors of lung cancer screening and smoking cessation treatment use among Massachusetts Federally Qualified Health Centers (FQHC)s, and a stakeholder advisory group to synthesize these data and select implementation strategies that reflects the critical determinants and the strengths and resource constraints of the Federally Qualified Health Centers (FQHC) context.

Detailed Description

Aim 1) To design an implementation strategy that targets critical components in the delivery of SCT or LCS services for patients who smoke.

Aim 2) To assess the acceptability, appropriateness and feasibility of the implementation strategy among community health center staff.

Conditions

Smoking Cessation

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: OTHER
• Blinding Strategy: NONE

Study Groups

Stakeholder Advisory Group

To co-design an implementation strategy that targets critical components in the delivery of SCT or LCS services for patients who smoke.

Convene a stakeholder advisory group (CHC providers, quality improvement specialists, community engagement staff, and specialty providers) to review the results of the literature review and quantitative analysis of deidentified data in order to select a set of implementation strategies from a menu of strategies to implement. The team will meet with the stakeholder advisory group four times for 1-2 hours each.

Group Type: OTHER

Qualitative Group Interviews

Intervention Type: OTHER

One time interview, 60-90 minutes

Stakeholder advisory group

Intervention Type: OTHER

The team will meet with the stakeholder advisory group four times for 1-2 hours each

Interventions

Qualitative Group Interviews

One time interview, 60-90 minutes

Intervention Type: OTHER

Stakeholder advisory group

The team will meet with the stakeholder advisory group four times for 1-2 hours each

Intervention Type: OTHER

Eligibility Criteria

Inclusion Criteria

FQHC implementation team including staff in the intervention FQHCs and their lung screening partners

Exclusion Criteria

FQHC staff or partners who leave the organization before end of study

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 80 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

National Cancer Institute (NCI)

NIH

Sponsor Role: collaborator

University of Colorado, Denver

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Gina Kruse, MD, MPH

Role: PRINCIPAL_INVESTIGATOR

University of Colorado, Denver

Locations

Massacusetts General Hospital

Boston, Massachusetts, United States

Countries

United States

Provided Documents

Document Type: Study Protocol and Statistical Analysis Plan

View Document

Other Identifiers

P50CA244433-03S3

Identifier Type: NIH

Identifier Source: secondary_id

View Link

22-215

Identifier Type: -

Identifier Source: org_study_id